Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

29/02/2024 32 min
Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Listen "Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC"

Episode Synopsis

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.